Detailed information for compound 39021

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 406.453 | Formula: C19H22N2O6S
  • H donors: 3 H acceptors: 5 LogP: 1.3 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: ONC(=O)[C@H]1C[C@@H](O)CCN1S(=O)(=O)c1ccc(cc1)OCc1ccccc1
  • InChi: 1S/C19H22N2O6S/c22-15-10-11-21(18(12-15)19(23)20-24)28(25,26)17-8-6-16(7-9-17)27-13-14-4-2-1-3-5-14/h1-9,15,18,22,24H,10-13H2,(H,20,23)/t15-,18+/m0/s1
  • InChiKey: ACEUKQZDNBIUHG-MAUKXSAKSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens ADAM metallopeptidase domain 17 Starlite/ChEMBL References
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus multilocularis Blood coagulation inhibitor, Disintegrin Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus granulosus adam 17 protease Get druggable targets OG5_132656 All targets in OG5_132656
Schistosoma japonicum ko:K06059 a disintegrin and metalloproteinase domain 17, putative Get druggable targets OG5_132656 All targets in OG5_132656
Schistosoma mansoni ADAM17 peptidase (M12 family) Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus granulosus Blood coagulation inhibitor Disintegrin Get druggable targets OG5_132656 All targets in OG5_132656
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_132656 All targets in OG5_132656
Echinococcus multilocularis adam 17 protease Get druggable targets OG5_132656 All targets in OG5_132656

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi Matrixin family protein matrix metallopeptidase 1 (interstitial collagenase) 403 aa 401 aa 27.7 %
Brugia malayi Disintegrin family protein ADAM metallopeptidase domain 17 824 aa 724 aa 27.4 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Echinococcus granulosus polyADP ribose glycohydrolase 0.0171 0.2747 0.504
Echinococcus multilocularis a disintegrin and metalloproteinase with 0.0105 0.1144 0.0753
Entamoeba histolytica hypothetical protein 0.0171 0.2747 1
Brugia malayi metalloprotease disintegrin 16 with thrombospondin type I motif 0.0105 0.1144 0.3877
Echinococcus multilocularis poly(ADP ribose) glycohydrolase 0.0171 0.2747 0.592
Loa Loa (eye worm) Poly(ADP-ribose) glycohydrolase 0.0171 0.2747 0.2747
Echinococcus granulosus adam 17 protease 0.0245 0.4555 1
Trypanosoma cruzi poly(ADP-ribose) glycohydrolase, putative 0.0171 0.2747 0.5
Onchocerca volvulus Matrix metalloproteinase homolog 0.0058 0 0.5
Onchocerca volvulus Matrilysin homolog 0.0058 0 0.5
Schistosoma mansoni ADAM17 peptidase (M12 family) 0.0223 0.4013 1
Trypanosoma brucei poly(ADP-ribose) glycohydrolase, putative 0.0171 0.2747 0.5
Entamoeba histolytica poly(ADP-ribose) glycohydrolase, putative 0.0171 0.2747 1
Schistosoma mansoni poly(ADP-ribose) glycohydrolase 0.0171 0.2747 0.5588
Echinococcus multilocularis adam 17 protease 0.0223 0.4013 1
Loa Loa (eye worm) matrixin family protein 0.0064 0.0128 0.0128
Trypanosoma cruzi poly(ADP-ribose) glycohydrolase, putative 0.0171 0.2747 0.5
Brugia malayi Poly 0.0171 0.2747 1
Toxoplasma gondii poly(ADP-ribose) glycohydrolase 0.0171 0.2747 1
Echinococcus granulosus Blood coagulation inhibitor Disintegrin 0.014 0.1988 0.2957
Echinococcus granulosus a disintegrin and metalloproteinase with 0.0105 0.1144 0.0641
Echinococcus multilocularis Blood coagulation inhibitor, Disintegrin 0.014 0.1988 0.3473

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 9 nM Inhibition of human recombinant tumor necrosis factor-alpha converting enzyme. ChEMBL. 12951101
IC50 (binding) = 9 nM Inhibitory concentration against recombinant tumor necrosis factor alpha converting enzyme ChEMBL. 11992783
IC50 (binding) = 9 nM Inhibition of human recombinant tumor necrosis factor-alpha converting enzyme. ChEMBL. 12951101
IC50 (binding) = 9 nM Inhibitory concentration against recombinant tumor necrosis factor alpha converting enzyme ChEMBL. 11992783
IC50 (binding) = 8000 nM In vitro inhibition of matrix metalloprotease-1. ChEMBL. 12951101
IC50 (binding) = 8000 nM Inhibitory concentration of the compound against Matrix metalloproteinase-1 was determined ChEMBL. 11992783
IC50 (binding) = 8000 nM In vitro inhibition of matrix metalloprotease-1. ChEMBL. 12951101
IC50 (binding) = 8000 nM Inhibitory concentration of the compound against Matrix metalloproteinase-1 was determined ChEMBL. 11992783
IC50 (functional) uM Inhibition of TNF-alpha release was determined in LPS-stimulated human whole blood assay; not determined ChEMBL. 11992783
IC50 (functional) 0 uM Inhibition of TNF-alpha release was determined in LPS-stimulated human whole blood assay; not determined ChEMBL. 11992783

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.